Israel's SciVac eyes global expansion of 3G hepatitis B vaccine

(Reuters) - Israeli drug company SciVac is seeking U.S. approval for a widely used hepatitis B vaccine as part of a push for increased global sales of a product which it says could stem global growth in the disease.

SciVac's Sci-B-Vac, already given to the majority of Israeli children just after birth, comprises all three native proteins of the virus, compared with just one protein in an older vaccine from GlaxoSmithKline's called Engerix-B and cheaper copycats from China.

Dosage of Sci-B-Vac is just a quarter that of Engerix.


Labels: , , ,